Treatment of anaemia with darbepoetin alfa in systolic heart failure

Source: New England Journal of Medicine Area: News The findings of a study evaluating whether darbepoetin alfa improves clinical outcomes in patients with chronic systolic heart failure and non-iron-deficiency anaemia have been presented at the meeting of the American College of Cardiology and published early online in the New England Journal of Medicine.   The authors note that there is evidence to suggest that increasing haemoglobin (Hb) level with the use of erythropoiesis-stimulating agents (ESAs) may improve outcomes in patients with heart failure and anaemia, but it is not robust. Their study (Reduction of Events by Darbepoetin Alfa in Heart Failure [RED-HF]) randomised 2,278 patients with systolic heart failure and mild-moderate anaemia (Hb 9.0 to 12.0 g/dL) not due to iron deficiency to double-blind treatment with darbepoetin alfa (Hb target of 13 g/dL) (n=1,136) or placebo (n=1,142).   The primary outcome was a composite of death from any cause or hospitalisation for worsening heart failure - this ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news

Related Links:

Conclusions: Transcatheter closure of paravalvular leaks is a feasible and safe procedure with high rates of technical, echocardiographic and clinical success in the short and medium term. It is an adequate therapeutic alternative, mainly in high surgical risk patients and multiples comorbidities. PMID: 32459208 [PubMed - as supplied by publisher]
Source: Archivos de Cardiologia de Mexico - Category: Cardiology Authors: Tags: Arch Cardiol Mex Source Type: research
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
AbstractAimsAnaemia and iron deficiency (ID) are frequently found in patients with chronic heart failure (CHF) and associated with adverse outcome. However, it is unclear whether absolute [transferrin saturation (TSAT)
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
CONCLUSIONS: The prevalence of neoplasms in patients with TS is high. The clinical presentation is different in relation to patients who do not have neoplasms and they probably represent a risk factor for a worse hospital and long term prognosis. PMID: 32430206 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
Authors: Kuronuma K, Okumura Y, Morikawa T, Yokoyama K, Matsumoto N, Tachibana E, Oiwa K, Matsumoto M, Kojima T, Haruta H, Nomoto K, Sonoda K, Arima K, Kogawa R, Takahashi F, Kotani T, Ohkubo K, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A, SAKURA AF Registry Investigators Abstract Atrial fibrillation (AF) and heart failure (HF) often coexist. The aims of this study were to explore the factors associated with the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the association between prognosis and a history of HF or the serum NT-proBNP level in Japanese patients wit...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Authors: Saito Y, Aizawa Y, Iida K, Matsumoto N, Sezai A, Tanaka M, Okumura Y Abstract Risk stratification of patients with infective endocarditis (IE) is difficult. The Controlling Nutritional Status (CONUT) score is an index of immune function and nutritional status. We investigated the prognostic value of the CONUT score in IE and whether its prognostic value differed between IE patients with and without indications for surgery.Clinical records were retrospectively evaluated for 92 patients with IE treated at Nihon University Itabashi Hospital and Nihon University Hospital between January 2014 and May 2019. The ...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
ito N, Pujol R, Comin-Colet J Abstract INTRODUCTION AND OBJECTIVES: Treatment with intravenous iron in patients with heart failure (HF) and iron deficiency (ID) improves symptoms, however its impact on survival and safety is unknown. We aimed to evaluate the management of ID and anemia with intravenous iron in patients with HF and long-term safety of intravenous iron. METHODS: We evaluated anemia and ID in patients with chronic HF at 3 university hospitals. Anemia was defined using the World Health Organization definition and ID was defined as ferritin
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Eur J Intern Med Source Type: research
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusions MAP less than 65 mmHg for 10  min or more post-CPB is associated with an increased risk ofde novo postoperative renal replacement therapy. The association between intraoperative hypotension and AKI was weaker in comparison to factors such as renal insufficiency, heart failure, obesity, anemia, complex or emergent surgery, and new-onset postoperative atrial fibrillation. Nonetheless, post-CPB hypotension is a potentially easier modifiable risk factor that warrants further investigation.Editor ’s PerspectiveWhat We Already Know about This TopicPatients undergoing cardiac surgery with cardiopulmonary ...
Source: Anesthesiology - Category: Anesthesiology Source Type: research
In conclusion, the evidence for state‐of‐the‐art heart failure treatments with regard to exercise capacity and quality of life is limited and appears not robust enough to permit recommendations for heart failure. The treatment of co‐morbidities may be important fo r these patient‐related outcomes. Additional studies on functional capacity and quality of life in heart failure are required.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Review Source Type: research
More News: Anemia | Aranesp | Cardiology | Cardiovascular | Heart | Heart Failure | Study